![]() |
市場調查報告書
商品編碼
1520532
2024-2032 年抗纖溶藥物市場報告(按適應症、形式、最終用戶和地區)Antifibrinolytic Drugs Market Report by Indication, Form, End User, and Region 2024-2032 |
IMARC Group年全球抗纖溶藥物市場規模達169億美元。
抗纖溶藥物是指用於促進血栓形成,防止動脈、靜脈發生纖溶或阻塞的藥物。這些藥物抑制纖溶酶原的激活,從而防止纖維蛋白溶解並維持血栓穩定性。它們用於治療出血、血管腫瘤並緩解月經出血過多。它們也用於在侵入性手術期間或之後控制出血。一些常用的抗纖維蛋白溶解藥物包括氨甲環酸、抑肽酶、氨基己酸和絲氨酸蛋白酶抑制劑。它們廣泛用於治療口咽、鼻、胃腸道和子宮陰道內膜的黏膜出血。因此,它們廣泛應用於醫院、診所以及創傷和門診手術中心。
道路事故、創傷和各種出血性疾病發生率的上升是推動市場成長的關鍵因素之一。此外,廣泛採用抗纖溶藥物來防止月經過多的女性以及心血管和神經外科手術期間失血,這也推動了市場的成長。抗纖維蛋白溶解藥物對於防止血栓溶解和減少失血至關重要。與此一致的是,大眾健康意識的提高以及對遺傳性血管水腫和血友病可用治療替代方案的認知也有助於市場的成長。各種技術進步和擴大使用抗纖維蛋白溶解療法來減少骨科患者的輸血是其他生長誘導因素。藥廠也正在開發具有增強功效和生物吸收性的創新口服和靜脈注射藥物變體。其他因素,包括老年人口的增加和醫療基礎設施的顯著改善,預計將推動市場成長。
The global antifibrinolytic drugs market size reached US$ 16.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.2 Billion by 2032, exhibiting a growth rate (CAGR) of 3.97% during 2024-2032.
Antifibrinolytic drugs refer to the pharmaceutical medicines used for promoting the formation of blood clots to prevent fibrinolysis or blockage in arteries and veins. These drugs inhibit the activation of plasminogen, thereby preventing the lysis of fibrin and maintaining clot stability. They are used for the treatment of hemorrhages, vascular tumors and providing relief from heavy menstrual bleeding. They are also used for controlling bleeding during or after invasive surgeries. Some commonly available antifibrinolytic drugs include tranexamic acid, aprotinin, aminocaproic acid and serine protease inhibitors. They are widely used for the management of mucosal bleeding in the oropharynx, nose, gastrointestinal (GI) tract and uterine-vaginal linings. As a result, they are extensively used across hospitals, clinics and trauma and ambulatory surgical centers.
The rising incidence of road accidents, traumas and various bleeding disorders is one of the key factors driving the growth of the market. Moreover, the widespread adoption of antifibrinolytic drugs to prevent blood loss in women suffering from menorrhagia and during cardiovascular and neurosurgeries is providing a thrust to the market growth. Antifibrinolytic drugs are essential for preventing clot lysis and minimizing blood loss. In line with this, increasing health consciousness and awareness among the masses regarding the available treatment alternatives for hereditary angioedema and hemophilia are also contributing to the growth of the market. Various technological advancements and the increasing utilization of antifibrinolytic therapy to reduce transfusion in orthopedic patients are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing innovative oral and intravenous drug variants with enhanced efficacy and bio-absorbability. Other factors, including the rising geriatric population and significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global antifibrinolytic drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication, form and end user.
Gynecology
Hereditary Angioedema
Fibrinolytic Response Testing
Surgeries
Others
Oral
Injectable
Hospitals and Clinics
Ambulatory Surgical Centers
Trauma Centers
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being ACIC Pharmaceuticals Inc., Akorn Inc., Aurobindo Pharma Limited, Ferring Pharmaceuticals, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Viatris Inc. and Vitruvias Therapeutics Inc.